Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.17), $0.02 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $37.4 million versus the consensus estimate of $38.28 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.